Jul. 20 at 4:09 PM
$PMN The total overview of Promis Platform Medicine PMN310 and the targeted total revenue is approximately 20bn+:
The estimated global pharmaceutical revenue for 2026—including the newly added category of Alzheimer's disease—breaks down as follows.
Revenues approx.:
AD
$4.43 to 7.79 bn projected to rise sharply due to new antibodies including PMN310
Schizophrenia
$7.80 to 9.48 bn;
PD
$6.20 to 8.38 bn;
ALS
$0.95 to 1.03 bn;
HD
$720 to 868 mn;
FTD
$120 to 250 mn
MSA
$45 to 157 million.
Supplement:
AD 2026 (CAGR) Key Drivers & Leading Companies
approx. 9.2% – 19.5% (highest growth in the neuro sector) Paradigm shift: transition from purely symptomatic generics (such as donepezil) to expensive, disease-modifying antibodies.
Leading companies:
$ESALY $BIIB anti-amyloid antibody Leqembi (lecanemab).
$LLY Dominant player with Kisunla (donanemab).
https://www.promisneurosciences.com/news-media/press-releases/detail/269/promis-neurosciences-reports-first-human-evidence-of
